Barbara Wilmarth
Adult Health · Washington, DCNPI 1477582138
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 399 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 399 payments — averaging $23.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- MDD US Operations, LLC$2K
- Amneal Pharmaceuticals LLC$1K
- Acadia Pharmaceuticals Inc$1K
- Teva Pharmaceuticals USA, Inc.$860
- Supernus Pharmaceuticals, Inc.$473
- plus $2K from 16 others
What the payments were for
- Speaking & faculty fees$340%
- Food & beverage$9,37298%
- Education$1301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 106 | $2,024 |
| MDD US Operations, LLC | 21 | $1,633 |
| Amneal Pharmaceuticals LLC | 62 | $1,129 |
| Acadia Pharmaceuticals Inc | 55 | $1,035 |
| Teva Pharmaceuticals USA, Inc. | 32 | $860 |
| Supernus Pharmaceuticals, Inc. | 8 | $473 |
| Merz Pharmaceuticals, LLC | 16 | $348 |
| Sunovion Pharmaceuticals Inc. | 17 | $315 |
| Neurocrine Biosciences, Inc. | 10 | $269 |
| Kyowa Kirin, Inc. | 12 | $234 |
| Acorda Therapeutics, Inc | 12 | $202 |
| Eisai Inc. | 10 | $181 |
| Revance Therapeutics, Inc. | 2 | $158 |
| Abbott | 7 | $139 |
| Adamas Pharmaceuticals, Inc. | 7 | $122 |
| Otsuka America Pharmaceutical, Inc. | 6 | $111 |
| Lilly USA, LLC | 4 | $76 |
| Avion Pharmaceuticals | 3 | $67 |
| Boston Scientific | 2 | $65 |
| Lundbeck LLC | 2 | $41 |
| Avanir Pharmaceuticals, Inc. | 2 | $39 |
| Corium, LLC | 3 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,536 in reported general payments places this provider in the 95th percentile of 63 adult health providers in District of Columbia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 70 | $512,806 |
| ApokynApomorphine Hcl | 13 | $323,934 |
| RytaryCarbidopa/Levodopa | 229 | $275,382 |
| NourianzIstradefylline | 67 | $245,737 |
| GocovriAmantadine Hcl | 35 | $189,143 |
| InbrijaLevodopa | 11 | $68,365 |
| XadagoSafinamide Mesylate | 15 | $45,553 |
| CrexontCarbidopa/Levodopa | 27 | $30,517 |
| Rasagiline Mesylate | 124 | $26,577 |
| Rivastigmine | 63 | $17,975 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 16 | $2,475 |
| Memantine Hcl | 38 | $1,546 |
| Clonazepam | 44 | $943 |
| Escitalopram Oxalate | 46 | $858 |
| Donepezil Hcl | 52 | $738 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $1,035 | $512,80670 claims |
| Amneal Pharmaceuticals LLCRytary, Crexont, Pyridostigmine Bromide | $1,129 | $306,433271 claims |
| Kyowa Kirin, Inc.Nourianz | $234 | $245,73767 claims |
| MDD US Operations, LLCGocovri | $1,633 | $189,14335 claims |
| Acorda Therapeutics, IncInbrija | $202 | $68,36511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 63 adult health providers in District of Columbia.
Other adult health in Washington
- Maureen MoriartyWashington$237K
- Monica BaenaWashington$12K
- Payal KadakiaWashington$6K
- Aimee ChappellWashington$6K
- Sarah BottomleyWashington$5K
- Rachel BarishWashington$4K
- Jillian ThompsonWashington$3K
- Tracy HolzmanWashington$3K
- Jody BeckWashington$2K
- Jude NjokuWashington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.